Abbot Laboratories Whitepaper

Whitepaper: Considerations in Purchasing a LIMS

Randy C. Hice | Abbot Laboratories Many scientific enterprises find themselves in need of a Laboratory Information Management System (LIMS) to replace an incumbent system, whether an existing commercial application, an amalgam of systems, or an in-house solution. Once the decision has been made, the selection and deployment of a new LIMS should move quickly and decisively. This white paper …

quality control, QA, quality assurance, QA, QC, manufacturing, efficiency

Download: QA, QC practices in manufacturing to ensure efficiency & quality

Dr Pradeep Nagalkar, Head Quality Control (Bio. & Chem.), Haffkine Bio-Pharma. Corp. Ltd., Mumbai gave a presentation on QA, QC Practices in Manufacturing to Ensure Efficiency & Quality at BioPharma India Convention 2014. Download the presentation to learn: What is Quality Control Importance of Quality Control in Biopharmaceutical Industry Advantages of Quality Control What is Quality Assurance (QA) What is the difference between …

The World Cord Blood Congress is where experts like Cryo-Cell CSO Linda Kelley meet to network, learn from each other, and discuss the latest cord blood strategies and technology.

Cryo-Cell CSO on the Challenge of Transporting Fresh Cord Blood and its Impact on Quality

We were lucky to have Linda Kelley, Chief Scientific Officer of Cryo-Cell, present at the World Cord Blood Congress in 2013. You can now download her presentation slides from the event, where she addresses the challenge of transporting fresh cord blood and its impact on quality including viability and potency. While you’re viewing the slides, you can also view the …

Increasing struggles in cell therapies manufacturing as production ramps up

Even though there has been an increasing number of cell therapies advancing to late-stage clinical development, several aspects of cell therapy development continue to present considerable challenges for large scale commercialization. It is clear that production of biologics in general carries higher risks than of small molecules pharmaceuticals and this becomes even more evident as production of cell therapies ramps …